We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

Federal Judge Allows Nexium Reverse Payment Patent Settlement Suit to Proceed

19 September 2013

Antitrust, Competition and Economic Regulation Alert

Last week a federal judge in Massachusetts largely denied a series of motions seeking dismissal of various "pay-for-delay" claims brought by direct and indirect purchasers involving AstraZeneca's acid reflux drug Nexium. Although certain federal and state claims were trimmed on statute of limitation grounds, U.S. District Judge William Young let stand the core claims of the suit based on the alleged continuing harm flowing from the agreements. This ruling comes just months after the Supreme Court's long-awaited decision in FTC v. Actavis and is one of the first times a court has applied the rule of reason analysis as articulated by the Court.

Read More: Federal Judge Allows Nexium Reverse Payment Patent Settlement Suit to Proceed

The team

Loading data